Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond.When phosphodiesterase is mentioned, it usually refers to cyclic nucleotide phosphodiesterases, which are discussed below and have significant clinical implications. There are numerous other families of phosphodiesterases, however, including the phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, in addition to a large number of less well-studied small-molecule phosphodiesterases.A group of enzymes known as cyclic nucleotide phosphodiesterases breaks down the phosphodiester bond in the second messenger molecules cAMP and cGMP. Within subcellular domains, they control the cyclic nucleotide signaling's amplitude, duration, and localization. Therefore, PDEs play a crucial role in controlling the signal transduction process that these second messenger molecules mediate.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V72093 | PAT-347 | 1689554-51-5 | PAT-347 is an Autotaxin (ATX) inhibitor. |
|
V72035 | PDE1-IN-3 | 2370966-46-2 | PDE1-IN-3, compound 4 (WO2019156861), is a selective inhibitor of human phosphodiesterase 1 (PDE1). |
|
V78586 | PDE1-IN-5 | PDE1-IN-5 (Compound 10c) is a selective PDE1C inhibitor (IC50= 15 nM). | |
|
V72097 | PDE10-IN-2 | 1516895-53-6 | PDE10-IN-2 is a PDE10 inhibitor (antagonist) with IC50≦0.01 μM. |
|
V76651 | PDE10A-IN-2 hydrochloride | PDE10A-IN-2 HCl is a specific, orally bioactive inhibitor of phosphodiesterase 10A (PDE10A) with IC50 of 2.8 nM. | |
|
V79536 | PDE11A4-IN-1 | PDE11A4-IN-1 (compound 23b) is a potent and specific PDE11A4 inhibitor (antagonist) with IC50 of 12 nM. | |
|
V72047 | PDE2A-IN-1 | 2648290-28-0 | PDE2A-IN-1 is a phosphodiesterase 2A (PDE2A) inhibitor (antagonist) with IC50 of 1.3 nM. |
|
V83382 | PDE3B-IN-1 | ||
|
V72092 | PDE4-IN-12 | 2901084-32-8 | PDE4-IN-12 is a potent pan-PDE4 inhibitor (antagonist) with IC50s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI 2.71 and 4.27, respectively). |
|
V79934 | PDE4-IN-13 | PDE4-IN-13 is a PDE4 inhibitor (antagonist) with IC50 of 1.56 μM. | |
|
V72053 | PDE4-IN-14 | 2231329-25-0 | PDE4-IN-14 (Compound 1) is a PDE4 inhibitor that may be utilized in the study of PDE4-related diseases (such as inflammatory and immune diseases, cancer, and metabolic diseases, etc. |
|
V72090 | PDE4-IN-3 | 2755687-49-9 | PDE4-IN-3 is a novel orally bioactive PDE4 inhibitor (antagonist) with strong inhibitory affinity (b>IC50 = 4.2 nM). |
|
V70519 | PDE4-IN-4 | 1793069-00-7 | PDE4-IN-4 is an M3 antagonist (pIC50 = 10.2) and PDE4 inhibitor (pIC50 = 8.8) used in inhalation studies in pulmonary diseases. |
|
V72066 | PDE4-IN-5 | 2768626-06-6 | PDE4-IN-5 (compound 33a) is a potent and specific PDE4 inhibitor (IC50=3.1 nM). |
|
V72013 | PDE4B-IN-2 | 915082-52-9 | PDE4B-IN-2 is an orally bioactive, selective PDE4B inhibitor (antagonist) with IC50 of 15 nM. |
|
V72015 | PDE4B-IN-3 | 2819779-01-4 | PDE4B-IN-3 is a potent PDE4B inhibitor (antagonist) with IC50 of 0.94 μM. |
|
V72062 | PDE4B/7A-IN-1 | 2511632-25-8 | 1A/5-hydroxynitrile rubber 7 receptor antagonist (5-HT1 aki = 8 nm, kb= 0.04 nm; 5-nitrile rubber 7K I = 451 nm, kb= 460 nm), with PDE4B/PDE7A inhibitory activity (PDE4B ic50= 80.4 μM; Pde7a chip 50= 151.3 μM). |
|
V72058 | PDE4B/7A-IN-2 | 2511632-55-4 | 5-HT1A/5-HT7 receptor antagonist (5-HT1A Ki=8 nM, Kb=0.04 nM; 5-HT7 Ki=451 nM, Kb=460 nM) has PDE4B/PDE7A inhibitory activity (PDE4B IC50=80.4μM ; PDE7A IC50=151.3μM), its antidepressant-like effect is stronger than that of escitalopram, which is the reference active molecule. |
|
V79800 | PDE5-IN-10 | PDE5-IN-10 (compound 4b) is a potent PDE5 inhibitor (antagonist) with IC50 of 20 nM. | |
|
V79793 | PDE5-IN-11 | PDE5-IN-11 is a potent PDE5 inhibitor (antagonist) with IC50 of 40 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
